Ignite Creation Date:
2025-12-25 @ 2:37 AM
Ignite Modification Date:
2025-12-31 @ 10:17 AM
Study NCT ID:
NCT01465334
Status:
TERMINATED
Last Update Posted:
2023-08-29
First Post:
2011-10-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Sponsor:
Organization: